 OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec, a company developing late-stage intratumoral cancer immunotherapies, today announced the publication of positive TAVOTM monotherapy data in patients with metastatic melanoma in the Annals of Oncology. The publication titled, Intratumoral Delivery of Tavokinogene Telseplasmid Yields Systemic Immune Responses in Metastatic Melanoma Patients, features data previously highlighted at both American Association of Cancer Research AACR and the Melanoma Bridge annual meetings. Annals of Oncology is the official publication of the European Society for Medical Oncology. 